Crossmark

Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes

Crossref DOI link: https://doi.org/10.1186/s12885-018-4365-y

Published Online: 2018-04-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liutkauskiene, Sigita https://orcid.org/0000-0002-4142-3136
Grizas, Saulius

Jureniene, Kristina

Suipyte, Jorune

Statnickaite, Akvile

Juozaityte, Elona
License Information

Text and Data Mining valid from 2018-04-20
More Information

Article History

Received: 31 August 2017

Accepted: 12 April 2018

First Online: 20 April 2018

Ethics approval and consent to participate

: This study was approved by the Bioethics Center of Lithuanian University of Health Sciences. Individual written informed consent was unnecessary according to the Law of Lithuanian Bioethics Committee 2011 []. This study was retrospective and based on database extracted records and medical documentation. Analyzed data had been de-identified. Administrative permissions of the Kaunas Oncology Hospital and the Oncology Institute of Lithuanian University of Health Sciences was required and obtained in order to review patient records and use the data mentioned in the Methods.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below